Coegin Pharma

Coegin Pharma's INCI application for FOL005 was approved at the end of May 2024, and an INCI name was granted. This marked a significant milestone in the company's preparations for the global launch of a product series for hair growth, as an INCI approval is essential for marketing cosmetic products globally. The company has since chosen to trademark the name and can now announce the commercial ingredient brand name "Follicopeptide".

The official ingredient name that will appear in ingredient lists is "sh-Oligopeptide-128 SP", and the commercial ingredient brand name is "Follicopeptide".

"I am very pleased with the commercial name Follicopeptide and envision that it will signify a premium hair growth product. It will be a mark of quality, indicating that the product is effective and safe," says Jens Eriksson, CEO of Coegin Pharma.

INCI stands for "International Nomenclature of Cosmetic Ingredients" and is an international system for naming ingredients used in cosmetic products. This system is used globally, including in the USA, the EU, China, and Japan, which have all been identified as key markets for the launch of Follicopeptide. INCI ensures that ingredients are clearly and consistently labelled, making it easier for consumers and authorities to understand and compare ingredients.

For further information, please contact:
Jens Eriksson, CEO
Email: info@coeginpharma.com
Phone: +46 72 221 24 21

This document is a translation of the original Swedish press release. In case of any discrepancies, the Swedish version shall prevail.

About Coegin Pharma
Coegin Pharma is a Swedish biotech company with dermacosmetic innovations for hair growth and skin pigmentation, alongside groundbreaking drug candidates for the treatment of myocardial infarction and leukemia. Coegin is planning for the launch of its first product series for hair growth in 2025, followed by a skin pigmentation product in 2026. 

Coegin Pharma's shares are listed on NGM Nordic SME and Börse Stuttgart, and the company have a registered office in Lund, Sweden. 

For more information, please visit: coeginpharma.com/en